Clinical application of Vitek-derived minimum inhibitory concentration values: Proof of concept study
Author:
Open Access
- 31 March 2023
- journal article
- research article
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 38 (1) , 4
Abstract
Background: Minimum inhibitory concentration (MIC) values are useful in guiding appropriate antimicrobial therapy however, routine provision and interpretation of MIC values to guide clinical decision-making is challenging. Objectives: This proof of concept study aims to demonstrate the clinical utility and application of Vitek®-derived MIC values through categorisation of clinical isolates as wild type. Method: A random selection of clinically relevant Gram negative isolates routinely tested on the Vitek® instrument were included. The Vitek® MIC values, for selected antimicrobials at the lowest calling range of that card, were compared to the broth microdilution reference method. The specified end-point was concordance between the two results if the reference MIC was less than or equal to the EUCAST-defined epidemiological cut-off value (ECOFF) for that drug-bug combination. Results: A total of 525 isolates were included (468 Enterobacterales and 57 Pseudomonas aeruginosa), with an overall concordance rate of 96.4% (508/525). Correct ECOFF categorisation by the Vitek® was highest for ceftazidime and piperacillin (100%, n = 48 and n = 55, respectively) and lowest for cefepime (81.8%, n = 66). Conclusion: Vitek®-derived MIC values can be used to categorise organisms as wild-type if the MIC is reported at the card’s lowest calling range (≤) as there is high likelihood that the MIC is at or below the ECOFF. This has important implications for antimicrobial management, assisting in choice of agent and in improving probability of target attainment for desired pharmacodynamic targets which can translate into improved clinical outcomes. Contribution: Minimum inhibitory concentration data from an automated antimicrobial susceptibility testing instrument can be used to guide clinical decisions.Keywords
This publication has 10 references indexed in Scilit:
- How to: ECOFFs—the why, the how, and the don'ts of EUCAST epidemiological cutoff valuesClinical Microbiology and Infection, 2022
- The tension between clinical and microbiological relevance in applying clinical trial results for Gram negative bacterial infectionsClinical Microbiology and Infection, 2021
- Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patientsJournal of Antimicrobial Chemotherapy, 2020
- Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#Intensive Care Medicine, 2020
- Building a Better Test for Piperacillin-Tazobactam Susceptibility Testing: Would that It Were So Simple (It's Complicated)Journal of Clinical Microbiology, 2020
- Minimum inhibitory concentration-guided antimicrobial therapy – the Achilles heel in the antimicrobial stewardship agendaSouth African Medical Journal, 2018
- MIC-based dose adjustment: facts and fablesJournal of Antimicrobial Chemotherapy, 2017
- Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical PracticeClinical Infectious Diseases, 2015
- Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutionsThe Lancet Infectious Diseases, 2014
- DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?Clinical Infectious Diseases, 2014